Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody

Transplantation

Volumn 71, Issue 6, 2001, Pages 773-777

  Garrity Jr , Edward R ^a,b,c   Villanueva, Jaime ^a,b   Bhorade, Sangeeta M ^a,b   Husain, Aliya N ^a,d   Vigneswaran, Wickii T ^a,d  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Intermountain Healthcare   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

^d Department of Pathology ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AZATHIOPRINE; COTRIMOXAZOLE; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; ASPERGILLOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALIC INCLUSION BODY DISEASE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0035957199     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200103270-00015     Document Type: Article

References (24)

1. Analysis of time dependent risks for infection, rejection, and death after pulmonary transplantation
2. Results of single and bilateral lung transplantation in 131 consecutive patients
3. Analysis of risk factors for the development of bronchiolitis obliterans syndrome
4. Obliterative bronchiolitis after lung and heart-lung transplantation: An analysis of risk factors and management
5. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients
6. Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation: Early risk factors
7. Does histologic acute rejection in lung allografts predict the development of bronchiolitis obliterans?
8. The Loyola University lung transplant experience
9. Reduction of acute renal allograft rejection by daclizumab
10. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
11. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody
12. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection
13. The use of home spirometry in detecting acute lung rejection and infection following heart-lung transplantation
14. Standardization of spirometry 1994 update
15. Daclizumab rapidly saturates interleukin-2-receptor-alpha (CD25) on lymph node lymphocytes in children
16. Daclizumab: Outcome of phase III trials and mechanism of action
17. The use of antibodies against the IL-2 receptor in transplantation
18. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys
19. Daclizumab: Novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation
20. Improved results of lung transplantation for patients with cystic fibrosis
21. Graft vessel disease and obliterative bronchiolitis after heart/lung transplantation in children
22. Prevalence and outcomes of bronchiolitis obliterans syndrome after lung transplantation
23. Aspergillus and lung transplantation
24. Treatment of organ transplant-related lymphoma